How UVA Created Artificial Intelligence to Watch Over Patients With COVID-19 – University of Virginia

Even when the lights are low and the hallways quiet, save for the squeak of the night-shift nurses shoes, theres something else keeping a watchful eye on patients with serious coronavirus infections at UVA Health.

Here, patients with COVID-19 are monitored not just by a phalanx of nurses, physicians and specialists, but also by artificial intelligence software designed by a University of Virginia physician thats continuously computing their physiological data in order to predict whether life-threatening trouble might arise. Using numbers drawn every two seconds, and models updated every 15 minutes, the software actually predicts possible clinical issues before they happen, giving clinicians especially nurses critical time to head off a potential crisis hours before it strikes.

Since last July, patients with all kinds of serious illnesses convalescing on UVA Healths fourth floor in the Medical Intensive Care Unit, the Special Pathogens Unit, Cardiovascular Intensive Care Unit, Critical Care Unit, and the Surgical Intensive Care Unit and Intermediary Care Unit have the added benefit of CoMET, new software that uses continuous monitoring and computer algorithms to create a visual portrait of a patients risk of experiencing a serious event over the next 12 hours. Moment-to-moment data is drawn from a patients EKG, laboratory results and vital signs to create a graphic representing risk on a large LCD screen. That visual helps clinicians gauge patients stability and risk for clinical issues, and, if needed, to determine what actions should be taken to protect a patients health.

Like a barometer of risk, stable patients comets are small, yellow and nestle close to the X-Y axis on the display. But if the risk level rises, the comets grow, turn bright orange or deep red, and crawl up and across the screen like plump, shooting stars, indicating cardiovascular instability, respiratory instability or both.

These colorful graphics signal clinicians to employ proactive strategies to stabilize patients vital signs before serious medical events, such as sepsis, blood poisoning, respiratory distress or cardiac instability, and the need for ICU-level care happen. For one patient, nursing staff spotted an expanding comet and quickly adjusted oxygen flow, suctioned the patients mouth and closely monitored the patients status. For another patient, whose growing risk appeared along the cardiovascular axis, nurses alerted physicians to reassess red blood cell levels, ultimately deciding that the patient needed a transfusion.

For COVID patients, said CoMETs creator, UVA cardiologist Dr. Randall Moorman, the system is especially beneficial, given how quickly and unpredictably their prognoses can change.

Vital sign measurements and labs can come too late, Moorman, also a professor of medicine, explained, but early detection through predictive analytics has the power to improve patients outcomes, especially for catastrophic illnesses like COVID-19.

CoMET is also a boon given the most recent worldwide increase of COVID-19 cases.

Using precision predictive analytics systems like this one helps nurses initiate clinical response before the scenario becomes, quite literally, life and death, said Jessica Keim-Malpass, a professor in the School of Nursing and Moormans research partner. She published her research on CoMETs important aid to nurses on COVID units in the current issue of the International Journal of Nursing Studies Advances.

Keim-Malpass and UVA cardiologist Jamie Bourque recently began a two-year, randomized controlled study of the software across UVA Healths entire fourth floor, which includes the Coronary Intensive Care Unit and the Thoracic/Cardiovascular Intensive Care Unit, thanks to a $600,000 bequest from the Frederick Thomas estate. Over the next two years, theyll randomly assign a CoMET display to half the beds and compare the outcomes of patients in the experimental and control groups to determine the systems efficacy and impact.

Moorman has long been a pioneer in the field of predictive analytics. Twenty years ago, he and his coworkers discovered that premature babies exhibited abnormal heart rate patterns in the hours before being diagnosed with life-threatening sepsis, and developed a visual risk display similar to CoMETs called HeRO to alert clinicians to infants whose prognoses were growing worse. In the largest randomized trial of its kind, they found that 3,000 at-risk, low-birth-weight babies across nine hospitals who had a HeRO display at their bedside were 20% less likely to die.

CoMETs approach stands alone. Unlike other software that uses a point system or thresholds to calculate a patients risk for potential clinical issues, CoMET analyzes each new data point from the patients Electronic Health Record and bedside monitor, making sense of subtle changes across multiple predictors to continuously update and calculate their risk. Other patient monitoring systems offer a portrait of risk at four- or eight-hour intervals, or use alarms that contribute to alarm fatigue. (Another hospital study found that 90% of the 187 audible alarms that ring each day require no action.)

CoMETs value goes beyond predicting adverse events, too. With its bold visuals, it also enables clinicians to assess the impact of therapies in real time, enhances assessments and interventions through an additional health indicator, and gives nurses more autonomy and the ability to be proactive in their care delivery.

Moorman and Keim-Malpass say the new UVA Health study will provide another opportunity to fine-tune the technology in a moment when CoMET holds great promise for health systems seeking to improve their care of COVID patients.

In the fight against COVID-19, Keim-Malpass said, CoMET offers us the potential to change the clinical paradigm from reactive to proactive.

View post:
How UVA Created Artificial Intelligence to Watch Over Patients With COVID-19 - University of Virginia

Artificial Intelligence (AI) Market: To Receive Overwhelming Hike In Revenues By 2016 2024 KSU | The Sentinel Newspaper – KSU | The Sentinel…

According to a new market report pertaining to the globalartificial intelligence marketpublished by Transparency Market Researchthe global artificial intelligence market is projected to reachUS$ 5,508.4 Bnby2027. The artificial intelligence market is projected to expand at a CAGR of24.5%from2019to2027. Increasing dependency over automation is expected to drive the growth of the market. Over the forecast period, North America is anticipated to have the largest market share whereas Asia Pacific is expected to grow at the highest rate.

Request For Covid19 Impact Analysis Across Industries And Markets @https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=4674

Artificial Intelligence Market: Market Taxonomy

The global artificial intelligence market has been segmented in terms of type, application, and region. Based on type, the market has been segmented into artificial neural network, digital assistance system, embedded system, expert system and automated robotic system. Based on application, the market has been segmented into deep learning, smart robots, image recognition, digital personal assistant, querying method, language processing, gesture control, video analysis, speech recognition, context aware processing and cyber security.

Artificial Intelligence Market: Regional Outlook

North America is expected to dominate the artificial intelligence market during the forecast period. Asia Pacific is expected to see increasing growth in the artificial intelligence market. The artificial intelligence market in Middle East & Africa, Europe, and South America is also expected to expand rapidly during the forecast period.

The report provides in-depth segment analysis of the global artificial intelligence market, thereby providing valuable insights at macro as well as micro levels. Analysis of major countries which hold growth opportunities or account for significant share has also been included as part of geographic analysis of the artificial intelligence market.

Excerpt from:
Artificial Intelligence (AI) Market: To Receive Overwhelming Hike In Revenues By 2016 2024 KSU | The Sentinel Newspaper - KSU | The Sentinel...

How Artificial Intelligence is Revolutionizing Major Industries – United News of India

New Delhi, Jan 22, 2021: Artificial Intelligence (AI) is a catch-all term that refers to the simulation of human intelligence in machines, which results in traits like learning and problem-solving. On hearing these words, fans of science fiction might bring to mind images of intelligent robots intent on overthrowing or, at the very least, subjugating the human race. However, AI is a lot more varied and common than you might think. If youve experienced asking Siri to search for something online or used Google maps to make your way around a new place, then youve experienced just some of the benefits of artificial intelligence.

As technology becomes even more sophisticated, things which we once believed impossible are starting to become a reality. We owe a lot of this innovative progress to artificial intelligence and the brilliant people behind their programming. With such a powerful tool at their fingertips, many industries are continuously being revolutionized. As an example, here are a few of AIs applications to some of our major industries.

AI and Healthcare

Through studying and learning from large sets of data found in electronic health records, AI is able to expand physicians knowledge of similar symptomatic origins among numerous patients, even for rare diseases. AI is also able to speedily and thoroughly review medical literature and extract information about how the combination of certain types of drugs impacts the wellbeing of a patient who takes them together. This is a field in which the vast majority of us benefit greatly from any innovations. Therefore, it is wonderful to discover that AI has helped the medical field in better diagnosing diseases and in predicting possible complications from taking multiple medications simultaneously.

AI and The Automotive Industry

AI can be credited with changing not just what a vehicle can do, but also how it is made. AI has been utilized to alert drivers to dangerous situations and help them avoid accidents through monitoring dozens of sensors. Some companies like Google and Tesla have gone one step further and produced self-driving vehicles, which are constantly learning and improving their navigation systems, AI also protects the workers in manufacturing from injury. For instance, collaborative robots sense what their human counterparts are doing and adjust their movements to avoid injuring the people who work alongside them. Since most of us have driven, ridden in or been near a car at least once in our lives, it is indeed good news to hear that AI helps to make roads and production floors safer for everyone.

AI and Online Games

A pastime which is growing in popularity worldwide is online gaming. Avid gamers will surely thank AI when they find out just how much it contributes to a wonderful gaming experience. On a basic level, AI controls the non-player characters in each game such as enemy bots or even benign characters like helpful townspeople. The AI in some games even assesses a players ability and adjusts the level of difficulty accordingly. Most importantly, AI explores the patterns in how people use the game. This then helps developers determine how to improve it further. Whatever the online games platform we use, what is common among all of them is that they have been somehow transformed by AIs proverbial magic wand.

Those are just some of the positive changes that AI has brought into our lives. And this is only just the beginning. There are many upcoming innovations that we can look forward to.

Although artificial intelligence is certainly not without its drawbacks, one thing is abundantly clear: If used in the right way and for the right reasons, it can certainly change the world for the better.

(Disclaimer--Features may vary depending on the regions; subject to change without notice.)

Link:
How Artificial Intelligence is Revolutionizing Major Industries - United News of India

Heres Why Investors Should Pay Close Attention to Artificial Intelligence – Baystreet.ca

Artificial intelligence is ingrained into our lives. Its influencing our shopping choices online, helping us book meetings, and even finding the best deals. The auto industry is using AI to create driverless cars. The financial industry uses it to help organize operations, for bookkeeping, and to help reduce fraud and potential crime. Physicians can use it to identify correct medications based on patient analysis, and can even use it to help identify medical issues before they present themselves. Google and Facebook use it to deliver better advertising to users. Thats just a fraction of how AI is revolutionizing life as we know it. All as global companies race to embrace machine learning, and deep learning that will force computers to perform tasks that typically rely on humans.

In addition, JP Morgan analysts believe the market will grow to $58 billion by 2021. Better, Microsoft CEO Satya Nadella says AI is the "defining technology of our times. As we see advances in AI, some of the top companies to keep an eye on include Datametrex AI Ltd. (TSXV:DM)(OTC:DTMXF), Palantir Technologies Inc. (NYSE:PLTR), Baker Hughes Co. (NYSE:BKR), Fortinet Inc. (NASDAQ:FTNT), and Palo Alto Networks Inc. (NYSE:PANW).

Datametrex AI Ltd. (TSXV:DM)(OTC:DTMXF) BREAKING NEWS:Datametrex AI Ltd. is pleased to announce that it has renewed and extended its current sales agreements on January 15, 2021, with LOTTE Global Logis, LOTTE Duty-Free Shops, and LOTTE Home Shopping, LOTTE Super, collectively LOTTE for technology services and maintenance. The aggregate gross revenue from these agreements is approximately $500,000 CAD with the gross margin of $259,000. Datametrex is a continued preferred vendor partner for LOTTE, and vendors on this platform have demonstrated quality, reliability, and trustworthiness.

These extended agreements with LOTTE further confirm Datametrexs business strategy for generating revenue from its diverse portfolio of AI technology and cybersecurity products, commented Marshall Gunter, CEO of Datametrex.

Other related developments from around the markets include:

Palantir Technologies Inc. (NYSE:PLTR) announced the Army (PEO IEW&S) down-selected it to deliver a prototype for the first phase of the Armys Ground Station modernization in support of the Armys Tactical Intelligence Targeting Access Node (TITAN) program. The contract value for this phase is $8.5 million, with a potential contract value of approximately $250 million over all 4 phases. Palantir was awarded a Phase 1 Project Agreement through an Other Transaction Agreement (OTA) with Consortium Management Group, Inc. (CMG) on behalf of Consortium for Command, Control and Communications in Cyberspace (C5).

Baker Hughes Co. (NYSE:BKR) will hold a webcast onThursday, January 21, 2021to discuss the results for the fourth quarter and full year endingDecember 31, 2020. The webcast is scheduled to begin at9:00 a.m. Eastern Time(8:00 a.m. Central Time). A press release announcing the results will be issued at7:00 a.m. Eastern Time(6:00 a.m. Central Time).

Fortinet Inc. (NASDAQ:FTNT), a global leader in broad, integrated, and automated cybersecurity solutions, announced that it will hold a conference call to discuss its fourth quarter 2020 financial results onThursday, February 4at1:30 p.m. Pacific Time(4:30 p.m. Eastern Time).

Palo Alto Networks Inc. (NYSE:PANW) launched a rapid response program to help SolarWinds Orion customers navigate risks from cyberattacks. SolarWinds Orion products are currently being exploited by malicious actors to gain access to the company's systems, activity being tracked by Palo Alto Networks' Unit 42 as SolarStorm. In launching the program, Palo Alto Networks shared that its Cortex XDR platform had successfully prevented an attempted SolarStorm attack. As well as instantly blocking the attempt, the company's systems deployed a set of indicators of compromise to customer-facing Palo Alto Networks' products.

Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Winning Media is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement Winning Media has been paid three thousand five hundred dollars for advertising and marketing services for Datametrex AI Ltd. by a third party. We own ZERO shares of Datametrex AI Ltd. Please click here for full disclaimer.

Contact Information: 2818047972[emailprotected]

View post:
Heres Why Investors Should Pay Close Attention to Artificial Intelligence - Baystreet.ca

Artificial Intelligence is the Pharmaceutical Expert in Drug Development – Analytics Insight

Thepharmaceutical industryis a slow learner when it comes to implying digital health technology. Pharma companies have so far delayed the idea of usingartificial intelligence and machine learningstrategies to develop drugs. Artificial intelligence has the potential to make extraordinary innovation wave in drug discovery. However, the pharmaceutical sector should work on filling the gap between understanding these possibilities and applying them tothe drug discovery and developmentprocess.

Healthcare industry hasrapidly embraced artificial intelligenceinto the working system. AI and its sub-technologies are helping the medical industry on a large scale. However, the pharmaceutical industry is still on the initial stage of leveraging digital technologies to accelerate the drug development process. The main goal of drug discovery is to identify the medicine that acts beneficially on the body. Finding the right drug involves a lengthy process of carrying out large screen libraries of molecules that can specifically bind to a target molecule involved in a disease. The mission to find the right drug goes through numerous rounds of tests to develop it into a promising compound. According toTaconic Biosciencesstally, an incredible amount of time and money goes into drug development and bringing a drug to market costs about US$2.8 billion over 12+ years. Fortunately, artificial intelligence can help pharmaceutical industry to find the right drug and develop it. Artificial intelligence uses personified knowledge and learns from solutions it produces to address not only specific but also complex problems in medicine.

Drug development is a long process if conducted manually. Initially, researchers have to identify the target protein that is causing the disease and study it for a long time. Next, they try to find which component or a molecule would influence the protein. During this process, researchers make sure that inefficient components are kept aside and only safe, efficient components are taken further. The role of AI in drug discovery starts with finding the molecule that better address the protein. Researchers cant test the hundreds and thousands of molecules in market. It is both lengthy and expensive. Fortunately, AI platforms replace the long testing process with a simple analysis. Researchers feed in parameters into the AI platforms and make them run an analysis on the molecules. AI platform identifies the right component that can be used for drug development.

Even though deep neural network has been around the tech radar for decades, it got a wide range of attention only in 2012. Researchers from the University of Toronto won the ImageNet Large Scale Visual Recognition Challenge (ILSVR) are using deep neural network. Currently, pharmaceutical companies are using various types of deep neural networks to explore classical statistical techniques. The technology helps in finding the right molecule that is responsible for certain activities. Deep neural network gives an immediate indication to chemists of what to do in order to remove certain unwanted activities. This deep neural network model is also used by chemists to judge their compound ideas before deciding on whether to synthesize them or not

Healthcare data is huge and critical. Today, millions of research, feedback, reports, patient records and a whole lot of other things related to the healthcare industry are fed into AI in form of big data. Even though healthcare sector is pretty slow in availing solutions from them, medical institutions are trying their best to stay ahead in the race. Artificial intelligence systems are featured with an apt mechanism to go through data and make meaningful interpretations out of that. Deep learning programs run on the data and learn more about the proteins whose presence makes a difference between healthy patients and an ill one. Meanwhile, machine learning abilities strive to find and establish connections between proteins and diseases.

Before theCovid-19 pandemic outbreak, no one thought that a vaccine process could be fast-tracked so much. Generally, making a vaccine and testing it on a trial basis involves years of research and observation. However, the pandemic has broken the routine. Governments across the globe were running a race to come up with an effective vaccine as soon as possible. The funding into pharmaceutical industry also skyrocketed during the period. With accelerating the trials and emergency approvals on the bag, pharmaceutical companies leveraged AI to complement the vaccine making process.

AI in drug discovery (Phase 1): Discovering the right drug involves reading and analysing already existing literature and testing the ways potential drugs interact with targets. AI performs the tasks faster than humans and provides rapid results.

AI in preclinical development (Phase 2): During the preclinical development phase, the drug is tested on animals to see how they perform. Unveiling AI in this phase will help trials run smoothly and enable researchers to more quickly and successfully predict how a drug might interact with the animal model.

AI in clinical trials (Phase 3): Researchers begin testing the drug on human bodies during the clinical trial. AI can facilitate participant monitoring during clinical trials, generating a larger set of data more quickly and aid in participant retention by personalizing the trial experience.

Even though AI is helping drug discovery to a large range, it also raises some remarkable ethical questions. Patient data are hectic in healthcare industry. If these critical data gets to the hands of hackers, there are chances that itll be used for evil purposes. Henceforth, patient privacy needs to be maintained. Unlike many other sectors, there are no regulations or policies that direct drug makers to go on a drawn line. It is up to the pharmaceutical companies tosecure patient dataand use it in the right way.

Go here to read the rest:
Artificial Intelligence is the Pharmaceutical Expert in Drug Development - Analytics Insight

Government Will Increase Scrutiny on AI in Screening – ESR NEWS

Written By Employment Screening Resources (ESR)

Government agencies in the United States such as the Federal Trade Commission (FTC), the Consumer Financial Protection Bureau (CFPB), and the Equal Employment Opportunity Commission (EEOC) will increase scrutiny on how Artificial Intelligence (AI) is used in background screening, according to the ESR Top Ten Background Check Trends for 2021 compiled by leading global background check firm Employment Screening Resources (ESR).

In April 2020, the FTC the nations primary privacy and data security enforcer issued guidance to businesses on Using Artificial Intelligence and Algorithms written by Director of FTC Bureau of Consumer Protection Andrew Smith on the use of AI for Machine Learning (ML) technology and automated decision making with regard to federal laws that included the Fair Credit Reporting Act (FCRA) that regulates background checks.

Headlines tout rapid improvements in artificial intelligence technology. The use of AI technology machines and algorithms to make predictions, recommendations, or decisions has enormous potential to improve welfare and productivity. But it also presents risks, such as the potential for unfair or discriminatory outcomes or the perpetuation of existing socioeconomic disparities, Director Smith wrote in the FTC guidance.

The good news is that, while the sophistication of AI and machine learning technology is new, automated decision-making is not, and we at the FTC have long experience dealing with the challenges presented by the use of data and algorithms to make decisions about consumers, Smith wrote. In 2016, the FTC issued a report on Big Data: A Tool for Inclusion or Exclusion? In 2018, the FTC held a hearing to explore AI and algorithms.

In July 2020, the Consumer Financial Protection Bureau (CFPB) a government agency that helps businesses comply with federal consumer financial law published a blog on Providing adverse action notices when using AI/ML models that addressed industry concerns about how the use of AI interacts with the existing regulatory framework. One issue is how complex AI models address the adverse action notice requirements in the FCRA.

FCRA also includes adverse action notice requirements. For example, when adverse action is based in whole or in part on a credit score obtained from a consumer reporting agency (CRA), creditors must disclose key factors that adversely affected the score, the name and contact information of the CRA, and additional content. These notice provisions serve important anti-discrimination, educational, and accuracy purposes, the blog stated.

There may be questions about how institutions can comply with these requirements if the reasons driving an AI decision are based on complex interrelationships. Industry continues to develop tools to accurately explain complex AI decisions These developments hold great promise to enhance the explainability of AI and facilitate use of AI for credit underwriting compatible with adverse action notice requirements, the blog concluded.

In December 2020, ten Democratic members of the United States Senate sent a letter requesting clarification from the U.S. Equal Employment Opportunity Commission (EEOC) Chair Janet Dhillon regarding the EEOCs authority to investigate bias in AI driven hiring technologies, according to a press release on the website of U.S. Senator Michael Bennet (D-Colorado), one of the Senators who signed the letter.

While hiring technologies can sometimes reduce the role of individual hiring managers biases, they can also reproduce and deepen systemic patterns of discrimination reflected in todays workforce data Combatting systemic discrimination takes deliberate and proactive work from vendors, employers, and the Commission, Bennet and the other nine Senators wrote in the letter to EEOC Chair Dhillon.

Today, far too little is known about the design, use, and effects of hiring technologies. Job applicants and employers depend on the Commission to conduct robust research and oversight of the industry and provide appropriate guidance. It is essential that these hiring processes advance equity in hiring, rather than erect artificial and discriminatory barriers to employment, the Senators continued in the letter.

Machine learning is based on the idea that machines should be able to learn and adapt through experience and Artificial Intelligence refers to the broader idea that machines can execute tasks intelligently to simulate human thinking and capability and behavior to learn from data without being programmed explicitly, explained Attorney Lester Rosen, founder and chief executive officer (CEO) of ESR.

There have certainly been technological advances including back-office efficiencies and strides towards better integrations that streamline the employment screening process. However, does that qualify as machine learning or AI? In reality, true machine learning and artificial intelligence and the role it is likely to play in the future could fuel a new source of litigation for plaintiffs class action attorneys, said Rosen.

Proponents of AI argue that it will make the processes faster and take bias out of hiring decisions. It is doubtful that civil rights advocates and the EEOC will see it that way. The use of AI for decision making is contrary to one of the most fundamental bedrock principles of employment that each person should be treated as an individual, and not processed as a group or based upon data points, Rosen concluded.

Employment Screening Resources (ESR) a leading global background check provider that was ranked the number one screening firm by HRO Today in 2020 offers the award-winning ESR Assured Compliance system, which is part of The ESRCheck Solution, for real-time compliance that offers automated notices, disclosures, and consents for employers performing background checks. To learn more about ESR, visit http://www.esrcheck.com.

Since 2008, Employment Screening Resources (ESR) has annually selected the ESR Top Ten Background Check Trends that feature emerging and influential trends in the background screening industry. Each of the top background check trends for 2021 will be announced via the ESR News Blog and listed on the ESR background check trends web page at http://www.esrcheck.com/Tools-Resources/ESR-Top-Ten-Background-Check-Trends/.

NOTE: Employment ScreeningResources (ESR) does not provide or offer legal services or legal advice ofany kind or nature. Any information on this website is for educational purposesonly.

2021 Employment Screening Resources (ESR) Making copies of or using any part of the ESR News Blog or ESR website for any purpose other than your own personal use is prohibited unless written authorization is first obtained from ESR.

Read this article:
Government Will Increase Scrutiny on AI in Screening - ESR NEWS

Many Artificial Intelligence Initiatives Included in the NDAA – RTInsights

The NDAA guidelines reestablish an artificial intelligence advisor to the president and push education initiatives to create a tech-savvy workforce.

Theres plenty of debate surrounding why the USAs current regulatory stance on artificial intelligence (AI) and cybersecurity remains fragmented. Regardless of your thoughts on the matter, the recently passed National Defense Authorization Act (NDAA) includes quite a few AI and cybersecurity driven initiatives for both the military and non-military entities.

Its common to attach provisions to bills whenCongress, the Senate, or both know the bill must pass by a certain time. TheNDAA is one such bill. It has a yearly deadline every year or the countrysmilitary completely loses funding leading to lawmakers using it to pass lawsthat dont always make it on their own. (This years bill was initially vetoed.But the veto was overridden on January 1.)

The bill contains 4,500 pages worth ofinformation. Along with a few different initiatives, one particular moveoutlines both the military and the governments new interest in artificialintelligence.

One of the biggest moves in the bill has to do with the newly created Joint AI Center (JAIC). It moves from the under the supervision of the DODs CIO to the deputy secretary of defense. It moves higher in the DOD hierarchy, possibly underscoring just how crucial new cybersecurity initiatives are to the Department of Defense.

To that end, the JAIC is the Department of Defenses (DoD) AI Center of Excellence that provides expertise to help the Department harness the game-changing power of AI. The mission of the JAIC is to transform the DoD by accelerating the delivery and adoption of artificial intelligence. The goal is to use AI to solve large and complex problem sets that span multiple services, then ensure the Services and Components have real-time access to ever-improving libraries of data sets and tools.

The center will also receive its own oversightboard matching other bill provisions dealing with AI ethics and will soonhave acquisition authority as well. The center will be creating reportsbiannually about its work and its integration with other notable agencies.

The secretary of defense will also investigatewhether the DoD can use AI ethically, both acquired and developed technologies.This will happen within 180 days of the bills passing, creating a pressingdeadline for handling ethics issues surrounding both new technologies and the often-controversialuse of military AI-use.

The DoD will receive a steering committee onemerging technology as well as new hiring guidelines for AI-technologists. Thedefense department will also take on five new AI-driven initiatives designed toimprove efficiency at the DoD.

The second massive provision in the bill is a large piece of cybersecurity legislation. The Cyberspace Solarium Commission worked on quite a few pieces of legislation that made it into the bills final version. The bill creates a White House cyber director position. It also gives the Cybersecurity and Infrastructure Security Agency (CISA) more authority for threat hunting.

It directs the executive branch to conductcontinuity of the economy planning to protect critical economicinfrastructure in the case of cyberattacks. It also establishes a joint cyberplanning office at CISA.

The Cybersecurity Security Model Certification(CMMC) will fall under the Government Accountability Office, and the governmentwill require regular briefings from the DoD on its progress. CMMC is thegovernments accreditation body, and this affects anyone in the defensecontract supply chain.

Entities outside the Department of Defensewill have new initiatives as well. The National AI Initiative hopes toreestablish the United States as a leading authority and provider of artificialintelligence. The initiative will coordinate research, development, anddeployment of new artificial intelligence programs among the DOD as well ascivilian agencies.

This coordination should help bring coherenceand consistency to research and development. In the past, critics have cited alack of realistic and workable regulations as a clear reason the United Stateshas fallen behind in AI development.

It will advise future presidents on the stateof AI within the country to increase competitiveness and leadership. Thecountry can expect more training initiatives and regular updates about thescience itself. It will lead and coordinate strategic partnerships andinternational collaboration with key allies and provide those opportunities tothe US economy.

AI bias is a huge concern among business and US citizens, so the National AI Initiative Advisory Committee will also create a subcommittee on AI and law enforcement. Its findings on data security, and legal standards could affect how businesses handle their own data security in the future.

The National Science Foundation will runawards, competitions, grants, and other incentives to develop trustworthy AI.The country is betting heavily on new initiatives to increase trust among USconsumers as AI becomes a more important part of our lives.

NIST will expand its mission to createframeworks and standards for AI adoption. NIST guidelines already offercompanies a framework for assessing cybersecurity. The updates will helpdevelop trustworthy AI and spell a pathway for AI adoption that consumers willtrust and embrace.

As countries scramble to first place in AIreadiness, these initiatives hope to fix some key gaps leading to the USslagging authority. The NDAA guidelines reestablish an AI-advisor to thepresident and push education initiatives to create a tech-savvy workforce.

It also helps create guidelines for businesses already frantically adopting AI-driven initiatives, providing critical guidance for cybersecurity and sustainability frameworks. Between training and NIST frameworks, businesses could see a new era of trustworthy and ethical AI the sort that creates real insights and efficiency while mitigating risk.

Other countries are investing heavily in AIdevelopment, so new and expanded provisions will help secure the United Statesplace as a world leader in AI. Governmental funding and collaboration withcivilian researchers and development teams is one way the US can remain trulycompetitive in new technology the presence of such a robust body ofAI-focused legislations suggests lawmakers are making this a priority.

Excerpt from:
Many Artificial Intelligence Initiatives Included in the NDAA - RTInsights

BLOG: Artificial Intelligence for Clinical Decision Support and Increased Revenues – Imaging Technology News

The landscape at the Radiological Society of North Americas 2020 (RSNA20) conference was different for everyone this year attendees and exhibitors alike as we all grappled with the third wave of COVID-19. Through its virtual presence, Konica Minolta highlighted how their advancements in the artificial intelligence (AI) segment are transforming the practice of radiology in two specific areas: clinical decision support for imaging and increasing revenue through natural language understanding (NLU).

To further these efforts, Konica Minolta has partnered with 1QBit, an advanced and quantum computing software company with a strong focus on AI, based in Canada. 1QBit uses sophisticated techniques to tackle computationally intractable problems, and both companies share the same goal. Its really important to improve patient care with one goal, and that's with quality systems, said Kevin Borden, Vice President of HCIT Product at Konica Minolta Healthcare. To reach this goal, we partnered with 1QBit to provide an unmatched suite of tools to assist radiologists and radiology practices.

1QBit has a team of machine learning scientists, researchers and software developers who look at various industries with computationally difficult problems and identify where computing could help solve them. We have spent a fair amount of time and investment building our healthcare vertical. We have learned from working in different computing paradigms and distilled that learning to the classical world of computation where we build responsible solutions based on solid science, explained Deepak Kaura, M.D., who is the Chief Medical Officer of 1QBit, and also a practicing radiologist. The partnerships primary focus is on two specific areas: X-ray clinical decision support and NLU.

Konica Minoltas Exa Platform is unique in that it has a single database across all modules RIS, PACS and Billing. Within this integrated platform, the Exa system can incorporate various applications that provide tools and resources.

It's truly one application, and not separate databases, integrated together, Borden said. Its a complete platform with specialized viewing that includes 3-D mammo, echo stress and orthopedic toolsets.

This tight integration provides many partnership opportunities, the first being the technology that 1QBit has spent nearly three years developing called XrAI. XrAI is a decision support tool that uses machine learning to identify lung abnormalities and its algorithm works within the Konica Minolta Exa platform.

We see very few solutions out there that attempt to provide a comprehensive review of abnormality detection in the lungs and pleural spaces. These tools have not received regulatory approval yet, said Kaura. Weve trained our algorithm on about 500,000 different images and I think its important to recognize that the training dataset was really diverse. It was demographically diverse all these radiographs were taken using different X-ray machines across a variety of institutions in Canada. We then conducted a clinical trial and the first randomized control trial on the use of AI in the clinical space. The results of that trial were enlightening in that physicians who used XrAI demonstrated significantly improved detection of abnormalities on chest radiographs. We've submitted that for peer reviewed publication.

Kaura stressed the strength of the data gathered and the strength of the performance of the algorithm. As a result, they received Health Canada Class III Medical Device approval. It's the first time in Canadian history that any AI tool has received Class III Medical Device clearance, and now we've fully integrated into the workflows with Konica Minolta, he stated. At present, we're deploying across Canada and its very exciting to see a significant rollout of an imaging-based AI like this. As our partnership with Konica Minolta grows, we anticipate expansion of the solution within and beyond Canada.

One of the synergies that both companies agreed on from the first meeting was giving the radiologist the chance to actually make the diagnosis, while still allowing for adjustments. XrAI allows the radiologist to adjust the threshold of what he or she might deem a finding versus AI actually telling the clinician that this is a positive finding with no threshold, explained Borden. I think that's very important, and what we've done here in terms of the algorithm is one of the first we've seen rightly so, we put the decision in the hands of the radiologists.

Kaura agreed, adding that most physicians who use the technology would recommend it to their colleagues and institutions, based on the above and the performance of the algorithm. Providing user-controlled transparency is a significant step towards engendering trust in clinical AI. We are confident that this empowerment of the radiologist will create the standard for displaying AI outputs in the future. Konica Minoltas single, tight interface of RIS/PACS lends itself perfectly to this unique approach, said Kaura.

Another area Konica Minolta and 1QBit are advancing is Natural Language Understanding (NLU) and how it relates to managing patient follow-up care. NLU represents the next evolution of Natural Language Processing (NLP). Historically, and before NLU, NLP worked by identifying words that were close together to determine conclusions about their meaning. NLPs negation algorithms relied on words that were in close proximity to the diagnosis term to accurately determine a positive or negative result. For example, in the phrase no pleural effusions, the NLP negation algorithm recognized the proximity of the word no to pleural effusions and interpreted accordingly.

This is a challenge, however, when analyzing long or compound sentences, where the negation terms are not in close proximity to the diagnosis terms. For example, in the phrase No consolidation, pulmonary edema or pleural effusions, NLP may not accurately interpret this to mean there are no pleural effusions, because the negating term no is more than three words away from pleural effusions.

In comparison, NLU uses a neural net-based model to actually understand the context of the entire conversation. The 1QBit NLU engine works to understand the full report, produce an overall result, and generate action items based on all information.

We are able to take a look at a radiology report and ask the question, Does this patient display any pulmonary abnormalities? and because the natural language understanding model actually understands the entire report, it then produces a result that says no, Kaura said.

This NLU technology can already be used to help identify and automate patient follow-ups that may be recommended in a radiology report. As a radiologist dictates a report, the NLU engine can take the plain text, process it, identify any necessary patient follow-ups, and then generate a structured schedule order that is sent to the Exa Platform for processing. The order can include the type of appointment, the body part, the time frame and the modality.

The natural language understanding model understands what things might be relevant to follow-up, Kaura said. Even if someone says a CT scan is recommended, it recognizes that that represents follow-up. There are a number of variants on how physicians and clinicians express what follow-up means, and our understanding models actually figure out what that is.

You can view Konica Minoltas AI solutions and more in their Virtual World at kmhealthcarevirtual.com.

Editor's note: This blog is the third in a series from Konica Minolta on technical innovation. The next blog will feature the power of the next generation of RIS. The first, BLOG: Zero-footprint Viewer with Server-side Rendering Pushes Imaging Forward During Pandemic, can be read here. The second, BLOG: Exa Gateway Offers a New Way to Deliver Teleradiology, can be read here.

Originally posted here:
BLOG: Artificial Intelligence for Clinical Decision Support and Increased Revenues - Imaging Technology News

2021 Will Bring AI, Social Determinants of Health into Focus – HealthITAnalytics.com

January 22, 2021 -After a turbulent, momentous year, many rang in 2021 eager for a fresh start. In healthcare, however, some things will remain the same: namely, the significance of artificial intelligence and social determinants of health data.

Listen to thefull podcastto hear more details. And dont forget to subscribe oniTunes,Spotify, orGoogle Podcasts.

In a recent episode, Healthcare Strategies analyzed these trends and other major expectations for 2021.

Throughout the pandemic, organizations leveraged AI and data analytics tools to track disease spread and assess patient risk. The crisis pushed academic institutions, health systems, and vendors to develop and refine their AI and machine learning capabilities, setting the stage for even more advanced technologies in 2021.

So far in the new year, researchers have used AI to predict the likelihood of prostate cancer recurrence, assess tumor genetics, and analyze patient brain scans. As the year goes on, the industry will likely see organizations use data analytics tools to enhance day-to-day operations, as well as visibility to keep up with the demand for virtual care.

Social determinants of health data will also play a critical role in the healthcare industry in 2021. While this information is typically difficult to access and share, COVID-19 made social determinants data a crucial asset for organizations seeking to target interventions and get ahead of poor outcomes.

Collaborations between health systems and community organizations became more widespread, a trend that will likely continue into 2021.

The heightened emphasis on social determinants of health during the pandemic has also led researchers to examine the non-clinical factors that impact patient health. A team from Michigan Medicine recently discovered that racial disparities in cancer and COVID-19 outcomes stem from very similar factors, a finding that could inform public health policies.

The similarities between COVID-19 issues and cancer disparities are uncanny,saidJohn M. Carethers, MD, John G. Searle Professor and Chair of Internal Medicine at Michigan Medicine.

In cancer we are seeing in slow motion what has been observed rapidly with COVID that the same conditions in our society put specific groups at risk for both. If we can fundamentally change socioeconomic inequality, we theoretically could reduce disparities in both diseases.

If 2020 forced healthcare to take a hard look at what needs improvement, 2021 will be a reflection of the progress the industry has made and how far it still has to go.

Go here to see the original:
2021 Will Bring AI, Social Determinants of Health into Focus - HealthITAnalytics.com

Global Healthcare Artificial Intelligence Report 2020-2027: Market is Expected to Reach $35,323.5 Million – Escalation of AI as a Medical Device -…

Dublin, Jan. 08, 2021 (GLOBE NEWSWIRE) -- The "Artificial intelligence in Healthcare Global Market - Forecast To 2027" report has been added to ResearchAndMarkets.com's offering.

Artificial intelligence in healthcare global market is expected to reach $35,323.5 million by 2027 growing at an exponential CAGR from 2020 to 2027 due to the gradual transition from volume to value-based healthcare

The surging need to accelerate and increase the efficiency of drug discovery and clinical trial processes, advancement of precision medicines, escalation of AI as a medical device, increasing prevalence of chronic, communicable diseases and escalating geriatric population and the increasing trend of acquisitions, collaborations, investments in the AI in healthcare market.

Artificial intelligence (AI) is the collection of computer programs or algorithms or software to make machines smarter and enable them to simulate human intelligence and perform various higher-order value-based tasks like visual perception, translation between languages, decision making and speech recognition.

The rapidly evolving vast and complex healthcare industry is slowly deploying AI solutions into its mainstream workflows to increase the productivity of various healthcare services efficiently without burdening the healthcare personnel, to streamline and optimize the various healthcare-associated administrative workflows, to mitigate the physician deficit and burnout issues effectively, to democratize the value-based healthcare services across the globe and to efficiently accelerate the drug discovery and development process.

Artificial intelligence in healthcare global market is classified based on the application, end-user and geography.

Based on the application, the market is segmented into Medical diagnosis, drug discovery, precision medicines, clinical trials, Healthcare Documentation management and others consisting of AI guided robotic surgical procedures and AI-enhanced medical device and pharmaceutical manufacturing processes.

The AI-powered Healthcare documentation management solutions segment accounted for the largest revenue in 2020 and is expected to grow at an exponential CAGR from 2020 to 2027. AI-enhanced Drug Discovery solutions segment is the fastest emerging segment, growing at an exponential CAGR from 2020 to 2027.

The artificial intelligence in healthcare global end-users market is grouped into Hospitals and Diagnostic Laboratories, Pharmaceutical companies, Research institutes and other end-users consisting of health insurance companies, medical device and pharmaceutical manufacturers and patients or individuals in the home-care settings.

Among these end users, Hospitals and Diagnostic Laboratories segment accounted for the largest revenue in 2020 and is expected to grow at an exponential CAGR during the forecasted period. Pharmaceutical companies segment is the fastest-growing segment, growing at an exponential CAGR from 2020 to 2027.

The artificial intelligence in healthcare global market by geography is segmented into North America, Europe, Asia-Pacific and the Rest of the world (RoW). North American region dominated the global artificial intelligence in healthcare market in 2020 and is expected to grow at an exponential CAGR from 2020 to 2027. The Asia-Pacific region is the fastest-growing region, growing at an exponential CAGR from 2020 to 2027.

The artificial intelligence in healthcare market is consolidated with the top five players occupying majority of the market share and the remaining minority share of the market being occupied by other players. Key Topics Covered:

1 Executive Summary

2 Introduction

3 Market Analysis3.1 Introduction3.2 Market Segmentation3.3 Factors Influencing Market3.3.1 Drivers and Opportunities3.3.1.1 Aiabetting the Transition from Volume Based to Value Based Healthcare3.3.1.2 Acceleration and Increasing Efficiency of Drug Discovery and Clinical Trials3.3.1.3 Escalation of Artificial Intelligence as a Medical Device3.3.1.4 Advancement of Precision Medicines3.3.1.5 Acquisitions, Investments and Collaborations to Open An Array of Opportunities for the Market to Flourish3.3.1.6 Increasing Prevalence of Chronic, Communicable Diseases and Escalating Geriatric Population3.3.2 Restraints and Threats3.3.2.1 Data Privacy Issues3.3.2.2 Reliability Issues and Black Box Reasoning Challenges3.3.2.3 Ethical Issues and Increasing Concerns Over Human Workforce Replacement3.3.2.4 Requirement of Huge Investment for the Deployment of AI Solutions3.3.2.5 Lack of Interoperability Between AI Vendors3.4 Regulatory Affairs3.4.1 International Organization for Standardization3.4.2 Astm International Standards3.4.3 U.S.3.4.4 Canada3.4.5 Europe3.4.6 Japan3.4.7 China3.4.8 India3.5 Porter's Five Force Analysis3.6 Clinical Trials3.7 Funding Scenario3.8 Regional Analysis of AI Start-Ups3.9 Artificial Intelligence in Healthcare FDA Approval Analysis3.10 AI Leveraging Key Deal Analysis3.11 AI Enhanced Healthcare Products Pipeline3.12 Patent Trends3.13 Market Share Analysis by Major Players3.13.1 Artificial Intelligence in Healthcare Global Market Share Analysis3.14 Artificial Intelligence in Healthcare Company Comparison Table by Application, Sub-Category, Product/Technology and End-User

4 Artificial Intelligence in Healthcare Global Market, by Application4.1 Introduction4.2 Medical Diagnosis4.3 Drug Discovery4.4 Clinical Trials4.5 Precision Medicine4.6 Healthcare Documentation Management4.7 Other Application

5 Artificial Intelligence in Healthcare Global Market, by End-User5.1 Introduction5.2 Hospitals and Diagnostic Laboratories5.3 Pharmaceutical Companies5.4 Research Institutes5.5 Other End-Users

6 Regional Analysis

7 Competitive Landscape7.1 Introduction7.2 Partnerships7.3 Product Launch7.4 Collaboration7.5 Up-Gradation7.6 Adoption7.7 Product Approval7.8 Acquisition7.9 Others

8 Major Companies8.1 Alphabet Inc. (Google Deepmind, Verily Lifesciences)8.2 General Electric Company8.3 Intel Corporation8.4 International Business Machines Corporation (IBM Watson)8.5 Koninklijke Philips N.V.8.6 Medtronic Public Limited Company8.7 Microsoft Corporation8.8 Nuance Communications Inc.8.9 Nvidia Corporation8.10 Welltok Inc.

For more information about this report visit https://www.researchandmarkets.com/r/dxs2ch

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Link:
Global Healthcare Artificial Intelligence Report 2020-2027: Market is Expected to Reach $35,323.5 Million - Escalation of AI as a Medical Device -...